140 related articles for article (PubMed ID: 36129801)
1. First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Karimaa M; Riikonen R; Kettunen H; Taavitsainen P; Ramela M; Chrusciel M; Karlsson S; Rummakko P; Simola O; Wohlfahrt G; Hakulinen P; Vuorela A; Joensuu H; Utriainen T; Fizazi K; Oksala R
Mol Cancer Ther; 2022 Dec; 21(12):1765-1776. PubMed ID: 36129801
[TBL] [Abstract][Full Text] [Related]
2. Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.
Fizazi K; Bernard-Tessier A; Roubaud G; Utriainen T; Barthélémy P; Fléchon A; van der Voet J; Gravis G; Ratta R; Jones R; Parikh O; Tanner M; Antonarakis ES; Baldini C; Peters N; Garratt C; Ikonen T; Pohjanjousi P; Joensuu H; Cook N
NEJM Evid; 2024 Jan; 3(1):EVIDoa2300171. PubMed ID: 38320513
[TBL] [Abstract][Full Text] [Related]
3. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
[TBL] [Abstract][Full Text] [Related]
4. ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Peltola KJ; Bono P; Jones RH; Vjaters E; Nykänen P; Vuorela A; Oksala R; Pohjanjousi P; Mustonen MVJ; Fizazi K; Massard C
Eur Urol Focus; 2020 Jan; 6(1):63-70. PubMed ID: 30194031
[TBL] [Abstract][Full Text] [Related]
5. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Fizazi K; Massard C; Bono P; Kataja V; James N; Tammela TL; Joensuu H; Aspegren J; Mustonen M
Eur Urol Focus; 2017 Dec; 3(6):606-614. PubMed ID: 28753849
[TBL] [Abstract][Full Text] [Related]
6. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
7. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
10. Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology.
Kango G; Malek R; Mannuel H; Hussain A
Curr Opin Oncol; 2024 May; 36(3):195-201. PubMed ID: 38573209
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study.
Massard C; Penttinen HM; Vjaters E; Bono P; Lietuvietis V; Tammela TL; Vuorela A; Nykänen P; Pohjanjousi P; Snapir A; Fizazi K
Eur Urol; 2016 May; 69(5):834-40. PubMed ID: 26463318
[TBL] [Abstract][Full Text] [Related]
12. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
13. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
14. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.
Shore ND; Tammela TL; Massard C; Bono P; Aspegren J; Mustonen M; Fizazi K
Eur Urol Focus; 2018 Jul; 4(4):547-553. PubMed ID: 28753851
[TBL] [Abstract][Full Text] [Related]
15. Steroidogenesis in zebrafish and mouse models.
Hsu HJ; Hsu NC; Hu MC; Chung BC
Mol Cell Endocrinol; 2006 Mar; 248(1-2):160-3. PubMed ID: 16356628
[TBL] [Abstract][Full Text] [Related]
16. The osteogenic transcription factor runx2 controls genes involved in sterol/steroid metabolism, including CYP11A1 in osteoblasts.
Teplyuk NM; Zhang Y; Lou Y; Hawse JR; Hassan MQ; Teplyuk VI; Pratap J; Galindo M; Stein JL; Stein GS; Lian JB; van Wijnen AJ
Mol Endocrinol; 2009 Jun; 23(6):849-61. PubMed ID: 19342447
[TBL] [Abstract][Full Text] [Related]
17. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
19. Bisphenol A down-regulates rate-limiting Cyp11a1 to acutely inhibit steroidogenesis in cultured mouse antral follicles.
Peretz J; Flaws JA
Toxicol Appl Pharmacol; 2013 Sep; 271(2):249-56. PubMed ID: 23707772
[TBL] [Abstract][Full Text] [Related]
20. Function of Cyp11a1 in animal models.
Hu MC; Hsu HJ; Guo IC; Chung BC
Mol Cell Endocrinol; 2004 Feb; 215(1-2):95-100. PubMed ID: 15026180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
